Ftse Mib
33.154,05
-0,10%
DAX
18.235,45
0,17%
S&P 500
5.460,48
-0,41%
NASDAQ
17.732,60
-0,71%
Bitcoin
61.038,28
1,20%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ RVL Pharmaceuticals PLC (RVLP) RVL Pharmaceuticals PLC (RVLP) Notizie

RVLP

RVL Pharmaceuticals (RVLP)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:RVLP
DataOraFonteTitoloSimboloCompagnia
17/01/202422:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVLPRVL Pharmaceuticals PLC
27/11/202312:50GlobeNewswire Inc.RVL Completes Financial RestructuringNASDAQ:RVLPRVL Pharmaceuticals PLC
16/11/202315:11Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:RVLPRVL Pharmaceuticals PLC
01/11/202321:27Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:RVLPRVL Pharmaceuticals PLC
23/10/202322:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVLPRVL Pharmaceuticals PLC
18/10/202322:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RVLPRVL Pharmaceuticals PLC
12/10/202312:50GlobeNewswire Inc.RVL Pharmaceuticals plc Announces Prepackaged Reorganization of Certain U.S. SubsidiariesNASDAQ:RVLPRVL Pharmaceuticals PLC
05/09/202313:45Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:RVLPRVL Pharmaceuticals PLC
31/08/202320:23Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:RVLPRVL Pharmaceuticals PLC
30/08/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RVLPRVL Pharmaceuticals PLC
25/08/202323:21Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:RVLPRVL Pharmaceuticals PLC
23/08/202323:30Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:RVLPRVL Pharmaceuticals PLC
23/08/202322:05GlobeNewswire Inc.RVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:RVLPRVL Pharmaceuticals PLC
17/08/202322:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RVLPRVL Pharmaceuticals PLC
16/08/202314:00GlobeNewswire Inc.RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesNASDAQ:RVLPRVL Pharmaceuticals PLC
14/08/202315:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RVLPRVL Pharmaceuticals PLC
14/08/202312:50GlobeNewswire Inc.RVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business ReviewNASDAQ:RVLPRVL Pharmaceuticals PLC
02/08/202314:30GlobeNewswire Inc.RVL Pharmaceuticals plc to Discuss Second Quarter 2023 Financial Results and Provide Commercial UpdateNASDAQ:RVLPRVL Pharmaceuticals PLC
05/07/202312:50GlobeNewswire Inc.RVL Pharmaceuticals plc Provides Business UpdateNASDAQ:RVLPRVL Pharmaceuticals PLC
16/06/202322:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RVLPRVL Pharmaceuticals PLC
15/06/202322:15GlobeNewswire Inc.RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General MeetingNASDAQ:RVLPRVL Pharmaceuticals PLC
11/05/202322:24Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:RVLPRVL Pharmaceuticals PLC
11/05/202312:50GlobeNewswire Inc.RVL Pharmaceuticals plc Reports First Quarter 2023 Financial Results; Provides Commercial UpdateNASDAQ:RVLPRVL Pharmaceuticals PLC
04/05/202312:50GlobeNewswire Inc.RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial UpdateNASDAQ:RVLPRVL Pharmaceuticals PLC
24/04/202322:26Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:RVLPRVL Pharmaceuticals PLC
24/04/202322:17Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:RVLPRVL Pharmaceuticals PLC
24/04/202322:13Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:RVLPRVL Pharmaceuticals PLC
03/04/202319:00GlobeNewswire Inc.RVL Pharmaceuticals Announces that Upneeq® Wins “Best Eye Drop for Drooping Lids” NewBeauty in 13th Annual Beauty AwardsNASDAQ:RVLPRVL Pharmaceuticals PLC
20/03/202311:50GlobeNewswire Inc.RVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Commercial UpdateNASDAQ:RVLPRVL Pharmaceuticals PLC
15/03/202311:50GlobeNewswire Inc.RVL Pharmaceuticals plc to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Commercial UpdateNASDAQ:RVLPRVL Pharmaceuticals PLC
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:RVLP

La tua Cronologia

TG
1MA
MACOM Technology Solutions
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network